A Randomized, Multicenter, Two-Arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QoL) Measures in Subjects With Relapsing Forms of Multiple Sclerosis Who Are Transitioning From Rebif (Interferon Beta-1a) to Rebif New Formulation (RNF).

Trial Profile

A Randomized, Multicenter, Two-Arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QoL) Measures in Subjects With Relapsing Forms of Multiple Sclerosis Who Are Transitioning From Rebif (Interferon Beta-1a) to Rebif New Formulation (RNF).

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Feb 2015

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms REQOL
  • Sponsors EMD Serono
  • Most Recent Events

    • 24 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Sep 2009 Planned end date changed from 1 Aug 2008 to 1 Nov 2009 as reported by ClinicalTrials.gov.
    • 09 Sep 2009 Actual patient number (232) and additional lead trial investigator (Dangond F) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top